Genmab A/S
CSE:GMAB

Watchlist Manager
Genmab A/S Logo
Genmab A/S
CSE:GMAB
Watchlist
Price: 1 363.5 DKK -0.58% Market Closed
Market Cap: 90.3B DKK

EV/EBIT
Enterprise Value to EBIT

9.4
Current
22.1
Median
3.8
Industry
Lower than median
Higher than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
9.4
=
Enterprise Value
66.5B DKK
/
EBIT
7.1B DKK
EBIT Growth EV/EBIT to Growth
DK
Genmab A/S
CSE:GMAB
Average EV/EBIT: 20
9.4
19%
0.5
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -208 527.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
25.8
28%
0.9
US
Amgen Inc
NASDAQ:AMGN
29.5
31%
1
US
Gilead Sciences Inc
NASDAQ:GILD
13.7
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.7
15%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -521.3 N/A N/A
AU
CSL Ltd
ASX:CSL
21.7
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12
17%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.3 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -197.7 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
8.2
2-Years Forward
EV/EBIT
6.9
3-Years Forward
EV/EBIT
5.6